Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share. Recent Insider Transactions • Jun 12
Founder & Director recently bought €1.5m worth of stock On the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares. 공시 • Apr 29
CellaVision AB (Publ) Announces Board Appointments CellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors. 공시 • Apr 18
CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-Election CellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member. 공시 • Apr 10
CellaVision AB (publ) to Report Q1, 2026 Results on Apr 24, 2026 CellaVision AB (publ) announced that they will report Q1, 2026 results at 7:20 AM, Central European Standard Time on Apr 24, 2026 공시 • Feb 06
CellaVision AB (publ) announces Annual dividend, payable on May 06, 2026 CellaVision AB (publ) announced Annual dividend of SEK 2.7500 per share payable on May 06, 2026, ex-date on April 29, 2026 and record date on April 30, 2026. 공시 • Oct 22
CellaVision AB (publ), Annual General Meeting, Apr 28, 2026 CellaVision AB (publ), Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: lund Sweden Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €19.88, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €27.77 per share. 공시 • Oct 31
CellaVision AB (publ), Annual General Meeting, May 06, 2025 CellaVision AB (publ), Annual General Meeting, May 06, 2025, at 15:00 W. Europe Standard Time. Location: lund Sweden Buy Or Sell Opportunity • Oct 28
Now 21% undervalued Over the last 90 days, the stock has risen 4.0% to €21.95. The fair value is estimated to be €27.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023) Third quarter 2024 results: EPS: kr1.30 (up from kr1.09 in 3Q 2023). Revenue: kr178.7m (up 6.4% from 3Q 2023). Net income: kr31.1m (up 20% from 3Q 2023). Profit margin: 17% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 01
Founder & Director recently sold €2.4m worth of stock On the 27th of August, Christer Fahraeus sold around 100k shares on-market at roughly €24.10 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months. Buy Or Sell Opportunity • Jul 22
Now 24% undervalued Over the last 90 days, the stock has risen 5.5% to €20.95. The fair value is estimated to be €27.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has grown by 4.2%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Reported Earnings • Jul 22
Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023) Second quarter 2024 results: EPS: kr1.62 (up from kr1.46 in 2Q 2023). Revenue: kr187.8m (up 11% from 2Q 2023). Net income: kr38.5m (up 11% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 02
Now 24% undervalued Over the last 90 days, the stock has risen 7.9% to €21.85. The fair value is estimated to be €28.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Buy Or Sell Opportunity • Jun 27
Now 21% undervalued Over the last 90 days, the stock has risen 8.3% to €22.25. The fair value is estimated to be €28.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €22.65, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.46 per share. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023) First quarter 2024 results: EPS: kr1.26 (up from kr0.81 in 1Q 2023). Revenue: kr170.1m (up 22% from 1Q 2023). Net income: kr30.1m (up 57% from 1Q 2023). Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 14
Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022) Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Feb 24
Now 20% undervalued Over the last 90 days, the stock has risen 48% to €22.40. The fair value is estimated to be €28.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Buy Or Sell Opportunity • Feb 13
Now 21% undervalued Over the last 90 days, the stock has risen 51% to €21.20. The fair value is estimated to be €26.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Declared Dividend • Feb 09
Dividend of kr2.25 announced Shareholders will receive a dividend of kr2.25. Ex-date: 6th May 2024 Payment date: 13th May 2024 Dividend yield will be 9.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 08
Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022) Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to €23.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.37 per share. Buy Or Sell Opportunity • Jan 26
Now 25% undervalued Over the last 90 days, the stock has risen 53% to €16.08. The fair value is estimated to be €21.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Buying Opportunity • Dec 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 8.1%. The fair value is estimated to be €19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. Revenue is forecast to grow by 31% in 2 years. Earnings is forecast to grow by 60% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €12.48, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.01 per share. Reported Earnings • Oct 28
Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022) Third quarter 2023 results: EPS: kr1.09 (up from kr0.43 in 3Q 2022). Revenue: kr167.9m (up 19% from 3Q 2022). Net income: kr26.0m (up 150% from 3Q 2022). Profit margin: 16% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. 공시 • Oct 11
CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023 CellaVision AB (publ) announced that they will report Q3, 2023 results at 7:20 AM, Central European Standard Time on Oct 25, 2023 Buying Opportunity • Sep 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be €17.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 8.4%. Revenue is forecast to grow by 33% in 2 years. Earnings is forecast to grow by 95% in the next 2 years. Reported Earnings • Jul 20
Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022) Second quarter 2023 results: EPS: kr1.46 (down from kr1.56 in 2Q 2022). Revenue: kr169.7m (down 7.6% from 2Q 2022). Net income: kr34.7m (down 6.8% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. 공시 • Jul 07
CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023 CellaVision AB (publ) announced that they will report Q2, 2023 results at 7:20 AM, Central European Standard Time on Jul 20, 2023 New Risk • Jun 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €14.96, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.46 per share. Upcoming Dividend • May 01
Upcoming dividend of kr2.25 per share at 1.3% yield Eligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (1.6%). Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €15.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.51 per share. Reported Earnings • Apr 16
Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021) Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Buying Opportunity • Mar 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Buying Opportunity • Feb 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 9.3%. The fair value is estimated to be €23.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Reported Earnings • Feb 09
Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021) Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Buying Opportunity • Feb 09
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be €22.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%. 공시 • Feb 08
Cellavision AB (Publ) Proposes Dividend for 2022 The Board of Directors of CellaVision AB (publ) proposed an increased dividend to SEK 2.25 per share for 2022 (SEK 2.00 per share). Buying Opportunity • Jan 13
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be €23.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 17% share price gain to €23.45, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 29x in the Medical Equipment industry in Europe. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.85 per share. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment deteriorated over the past week After last week's 26% share price decline to €18.60, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.36 per share. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021) Third quarter 2022 results: EPS: kr0.43 (down from kr1.09 in 3Q 2021). Revenue: kr141.0m (up 6.9% from 3Q 2021). Net income: kr10.4m (down 60% from 3Q 2021). Profit margin: 7.4% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 15% share price gain to €27.90, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.00 per share. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €23.15, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.91 per share. 공시 • Jul 28
CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology Laboratories On July 27, 2022, CellaVision® announces the launch of DIFF-Line TM by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago. DIFF-Line TM by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox. CellaVision® DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020. RAL® SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market now July 27, 2022. RAL® StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals. Reported Earnings • Jul 21
Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021) Second quarter 2022 results: EPS: kr1.56 (up from kr1.30 in 2Q 2021). Revenue: kr183.6m (up 36% from 2Q 2021). Net income: kr37.3m (up 20% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 10%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • May 11
First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021) First quarter 2022 results: EPS: kr1.61 (up from kr1.19 in 1Q 2021). Revenue: kr162.4m (up 21% from 1Q 2021). Net income: kr38.4m (up 35% from 1Q 2021). Profit margin: 24% (up from 21% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • May 05
Upcoming dividend of kr2.00 per share Eligible shareholders must have bought the stock before 12 May 2022. Payment date: 18 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.2%). Reported Earnings • Apr 23
Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020) Full year 2021 results: EPS: kr5.26 (up from kr3.75 in FY 2020). Revenue: kr565.6m (up 20% from FY 2020). Net income: kr125.3m (up 40% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 15% share price gain to €29.78, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €31.82 per share. 공시 • Feb 06
Cellavision AB (Publ) Proposes Dividend for 2021 The Board of Directors of CellaVision AB (publ) proposed a dividend of SEK 2.00 per share for 2021 as compared to SEK 0.75 per share a year ago. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improved over the past week After last week's 16% share price gain to €31.86, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.88 per share. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr132.0m (up 50% from 3Q 2020). Net income: kr26.1m (up 96% from 3Q 2020). Profit margin: 20% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue. Recent Insider Transactions • Aug 25
Founder & Director recently sold €1.1m worth of stock On the 23rd of August, Christer Fahraeus sold around 24k shares on-market at roughly €45.43 per share. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months. Reported Earnings • Jul 22
Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: kr135.5m (up 15% from 2Q 2020). Net income: kr31.0m (up 14% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020). Executive Departure • May 04
Independent Chairman of the Board Sören Mellstig has left the company On the 29th of April, Sören Mellstig's tenure in the role of Independent Chairman of the Board ended. As of December 2020, Sören personally held 42.94k shares (€1.3m worth at the time). A total of 2 executives have left over the last 12 months. 공시 • Apr 30
CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021 The AGM of CellaVision AB (publ) resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021. Upcoming Dividend • Apr 24
Upcoming dividend of kr0.75 per share Eligible shareholders must have bought the stock before 30 April 2021. Payment date: 06 May 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.0%). Reported Earnings • Apr 11
Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses. Analyst Estimate Surprise Post Earnings • Feb 06
Revenue misses expectations Revenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 23%, compared to a 14% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Feb 06
Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses. Is New 90 Day High Low • Jan 22
New 90-day high: €32.02 The company is up 11% from its price of €28.88 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.95 per share. Is New 90 Day High Low • Oct 29
New 90-day low: €27.24 The company is down 5.0% from its price of €28.80 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.69 per share. Valuation Update With 7 Day Price Move • Oct 26
Market pulls back on stock over the past week After last week's 16% share price decline to kr27.84, the stock is trading at a trailing P/E ratio of 77.3x, down from the previous P/E ratio of 92.2x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total returns to shareholders over the past year are 9.6%. 공시 • Oct 15
Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision AB The Nomination Committee of CellaVision AB announced that the Chairman of the Board, Sören Mellstig, has declined re-election at the 2021 Annual General Meeting. Is New 90 Day High Low • Oct 01
New 90-day high: €33.86 The company is up 26% from its price of €26.78 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.15 per share. 